Schering Corporation

Intervet Inc.

Intervet International B.v.

Merck Sharp + Dohme Corp.

Yuguang Wang

Samuel Chackalamannil

Yan Xia

Craig D Boyle

William J Greenlee

Andrew William Stamford

Sundeep Dugar

John W Clader

Wei K Chang

Martin C Clasby

Joseph A Kozlowski

Michael J Green

Stuart W McCombie

Kun Liu

Dong-Ming Shen

Wayne D Vaccaro

Wenxue Wu

Derek B Lowe

Robert D McQuade

Lian-Yong Chen

Margaret E Browne

Jack D Scott

Peter J Sinclair

Zhicai Wu

Mariappan Chelliah

Joel G Berger

Margaret H Sherlock

Richard Thomas Beresis

Theodros Asberom

Enrico P Veltri

Wing C Tom

Susan F Vice

Dmitri A Pissarnitski

Anthony K Ogawa

Jayaram R Tagat

Ruo Xu

Ping Lan

Changhe Qi

Allen Barnett

Michael P Graziano

John Qiang Tan

Rudrajit Mal

Zhongxiang Sun

Min Shu

Ellen K Vande Bunte

Keith A Eagen

Yueqing Hu

Teddy Kosoglou

Madhu Chintala

Hong Shen

Alejandro Crespo

Robert J Devita

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein

Bicyclic and tricyclic derivatives as thrombin receptor antagonists

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

Cannabinoid receptor modulators

This application provides for oxazolisoquinoline derivatives of the formula 

Oxazoloisoquinoline derivatives as thrombin receptor antagonists

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein:

Thrombin receptor antagonists

A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders:  For example, a representative compound of the invention is: 

Xanthine phosphodiesterase V inhibitors

A compound represented by the structural formula    Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

Constrained himbacine analogs as thrombin receptor antagonists

A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.1), with the variables defined herein, which is useful for treating sexual dysfunction and other physiological disorders: A representative example is:

Polycyclic guanine phosphodiesterase V inhibitors

The present invention discloses compounds, which are novel muscarinic receptor antagonists, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such muscarinic receptor antagonists as well as methods for using them to treat cognitive disorders such as Alzheimer's disease.

Muscarinic antagonists

Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.

1,4 Di-substituted piperidine muscarinic antagonists of formula I ##STR1## or an isomer, pharmaceutically acceptable salt, ester or solvate thereof, wherein

Ether muscarinic antagonists

Growing community of inventors

North Brunswick, NJ, United States of America

Yuguang Wang